Contact us Demo our platform

Case Study

Metabolon Elucidates Novel Biomarkers to Improve Busulfan Dosing Strategies

The Metabolon Global Discovery Panel helped this research group develop a more efficient method of estimating busulfan clearance.

Metabolon found that by analyzing plasma obtained two weeks before administering busulfan, 13 endogenous metabolomic compounds could accurately predict the clearance of intravenous busulfan, particularly in patients with slow clearance. These results demonstrate that metabolomics can guide busulfan dosage to ensure that each patient receives the appropriate drug dosage.

Talk With An Expert About Your Project

Metabolon found that by analyzing plasma obtained two weeks before administering busulfan, 13 endogenous metabolomic compounds could accurately predict the clearance of intravenous busulfan, particularly in patients with slow clearance. These results demonstrate that metabolomics can guide busulfan dosage to ensure that each patient receives the appropriate drug dosage.

Talk With An Expert About Your Project
busulfan

The Challenge: Improving Busulfan Dosing Strategies

Busulfan is a chemotherapy drug used to treat certain types of cancer, including chronic myeloid leukemia (CLM) and some types of non-Hodgkin’s lymphoma. Many patients also receive high-dose busulfan as part of a conditioning regimen before a bone marrow transplant.  Busulfan works by killing fast-growing cells, but also affects normal cells that divide quickly—this can lead to side effects such as low blood counts, nausea, and diarrhea. Pharmacokinetic (PK)-guided busulfan dosing strategies aim to achieve a target therapeutic level of the drug in the patient’s bloodstream while minimizing toxicity. Although PK-guided busulfan dosing is considered an effective way to ensure optimal busulfan efficacy, this process is resource-intensive, labor-intensive, and time-sensitive. Thus, alternative approaches are needed to determine the appropriate busulfan dose for each patient. Metabolomics could improve or ideally replace PK-guided busulfan dosing to achieve the desired therapeutic effect while minimizing the risk of toxicity.

Metabolon Insight: Metabolomics Can Elucidate Biomarkers Associated with Busulfan Clearance

This study utilized the Metabolon Global Discovery Panel to profile the plasma of patients two weeks before (n = 96) and immediately before (n = 132) busulfan administration.1 The panel’s unrivaled coverage of up to 5,400 semi-quantifiable metabolites offered this group the most comprehensive solution to elucidate endogenous metabolomic compounds (EMCs) or biomarkers associated with busulfan clearance from plasma.

The Solution: Metabolon Helped Identify 13 Biomarkers Associated with Busulfan Clearance

Metabolomics analysis revealed the presence of 841 EMCs in the plasma samples of patients before busulfan administration. The research group then evaluated whether the presence of certain EMCs could predict intravenous busulfan clearance. Statistical analysis of the plasma samples obtained immediately before busulfan administration identified 13 EMCs as predominantly associated with busulfan clearance. These EMCs included urate, mannonate, lysine, cortisone, and cortisol. These 13 EMCs were later used to create a linear prediction model that was shown to have strong predictive power. When this model was applied to the two-week-pre-busulfan samples, the predicted vs. actual busulfan clearance values were strongly correlated (R2 = 0.40). This model had the highest predictive power among patients with lower clearance (R2 = 0.53). Pathway enrichment analysis of all the EMCs showed that lysine degradation was the most significant pathway in both sample groups.

The Outcome: Metabolon Can Help Optimize Busulfan Dosing

The Global Discovery Panel helped this research group develop a more efficient method of estimating busulfan clearance. Metabolon found that by analyzing plasma obtained two weeks before administering busulfan, 13 endogenous metabolomic compounds could accurately predict the clearance of intravenous busulfan, particularly in patients with slow clearance. These results demonstrate that metabolomics can guide busulfan dosage to ensure that each patient receives the appropriate drug dosage. The study shows that metabolomics can be leveraged to identify new biomarkers, which can help optimize drug dosing.

References

1. McCune JS, Navarro SL, Baker KS, et al. Prediction of Busulfan Clearance by Predose Plasma Metabolomic Profiling. Clin Pharmacol Ther. Feb 2023;113(2):370-379. doi:10.1002/cpt.2794

Related Case Studies

See All Case Studies
✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.